Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 939-949, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sölétormos, G.
Right arrow Articles by Dombernowsky, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sölétormos, G.
Right arrow Articles by Dombernowsky, P.
Related Collections
Right arrow Laboratory Management
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2000;46:939-949.)
© 2000 American Association for Clinical Chemistry, Inc.

Articles

Progression Criteria for Cancer Antigen 15.3 and Carcinoembryonic Antigen in Metastatic Breast Cancer Compared by Computer Simulation of Marker Data

György Sölétormos1,2,3,a, Per Hyltoft Petersen4 and Per Dombernowsky2

Departments of
1 Clinical Biochemistry and
2 Oncology, Herlev Hospital, University of Copenhagen, 2720 Copenhagen, Denmark.
3 Department of Clinical Biochemistry, Hillerød Hospital, DK 3400 Hillerød, Denmark.

4 Department of Clinical Biochemistry, Odense University Hospital, 5000 Odense, Denmark.
a Address correspondence to this author at: Department of Clinical Biochemistry, Hillerød Hospital, Helsevej 2, DK 3400 Hillerød, Denmark. Fax 45-48-24-00-67; E-mail geso{at}fa.dk

Background: We investigated the utility of computer simulation models for performance comparisons of different tumor marker assessment criteria to define progression or nonprogression of metastatic breast cancer.

Methods: Clinically relevant values for progressive cancer antigen 15.3 and carcinoembryonic antigen concentrations were combined with representative values for background variations in a computer simulation model. Fifteen criteria for assessment of longitudinal tumor marker data were obtained from the literature and computerized. Altogether, 7200 different patients, each based on 50 measurements, were simulated. With a sampling interval of 4 weeks, the monitoring period for each event was ~3.8 years.

Results: Modulation of the background variation, the starting concentrations, and the cutoffs enabled identification of criteria that were robust against false-positive signals of progression.

Conclusions: The computer simulation model is a fast, effective, and inexpensive approach for comparing the diagnostic potential of assessment criteria during clinically relevant conditions of steady-state and progressive disease. The model systems can be used to generate tumor marker assessment criteria for a variety of malignancies and to compare and optimize their diagnostic performance.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
G. Soletormos, P. H. Petersen, and D. Nielsen
Computer-simulated Tumor-Marker Data Used to Compare Progression Criteria for Cytokeratin Tissue Polypeptide Antigen in Metastatic Breast Cancer
Clin. Chem., November 1, 2001; 47(11): 2035 - 2037.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. Soletormos and V. Schioler
Description of a Computer Program to Assess Cancer Antigen 15.3, Carcinoembryonic Antigen, and Tissue Polypeptide Antigen Information during Monitoring of Metastatic Breast Cancer
Clin. Chem., August 1, 2000; 46(8): 1106 - 1113.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.